CXCR6-based immunotherapy in autoimmune,cancer and inflammatory infliction  

作　　者：Tingting Li Jie Pan Hongqi Chen Yongliang Fang Yang Sun 

机构地区：[1]Department of Gastroenterology,the Second Medical Center,National Clinical Research Center for Geriatric Diseases,State Key Laboratory of Kidney Diseases,Chinese PLA General Hospital,Beijing 100853,China [2]State Key Laboratory of Pharmaceutical Biotechnology,Department of Biotechnology and Pharmaceutical Sciences,School of Life Sciences,Nanjing University,Nanjing 210023,China [3]Department of General Surgery,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China [4]Department of Urology,Boston Children’s Hospital,Departments of Microbiology and Surgery,Harvard Medical School,Boston,MA 02115,USA [5]Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy,Xuzhou Medical University,Xuzhou 221004,China

出　　处：《Acta Pharmaceutica Sinica B》2022年第8期3255-3262,共8页药学学报（英文版）

基　　金：supported by National Natural Science Foundation of China (Nos.91853109 and 81872877);Mountain-Climbing Talents Project of Nanjing University (Nanjing,China)。

摘　　要：T cells, including both CD4^(+) and CD8^(+)T cells, play a pivotal role in mediating various inflammation and immune disorders. A long-standing challenge in T cell-based immunotherapy is to precisely inactivate or delete the pathogenic T cells in inflammation and autoimmune diseases, or to selectively expand the immunocompetent T cell in tumor or other immune compromised situations, without inducing global immunosuppression or zealous immune activation respectively. To achieve this, a specific marker is needed to differentiate the pathogenic or immunocompetent T cell among the rests. Indeed,recent progress of immunology strongly suggests that CXC chemokine receptor 6(CXCR6, CD186) is such a kind of marker. Here, we review the emerging role of CXCR6 as a novel target for immunotherapy and discuss the underlying mechanism. We propose that CXCR6-based immunotherapy will play a significant role in autoimmune, nonalcoholic steatohepatitis(NASH), tumor, coronavirus disease 2019(COVID-19) and even ageing-related inflammatory infliction.

关 键 词：CXCR6 CXCL16 Inflammation Autoimmune diseases Tumor IMMUNOTHERAPY Nonalcoholic steatohepatitis COVID-19 

分 类 号：R392[医药卫生—免疫学]